Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Prifetrastat

Small molecule · Inhibitor of KAT6 (MYST histone acetyltransferase) (KAT6A) and KAT6B (MORF; MOZ2; MYST4) (KAT6B) · developed by Pfizer

Phase 1 Most advanced trial
PFE Developer
1 Registered trials

What is Prifetrastat?

Prifetrastat is an inhibitor of the MYST histone acetyltransferases KAT6A and KAT6B, which acetylate histones and other nonhistone substrates. By blocking this activity it is intended to disrupt gene expression in tumors that overexpress KAT6. It is being studied in renal impairment and in healthy adults.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PF-07248144
Drug type
Small molecule
Targets
KAT6 (MYST histone acetyltransferase) (KAT6A), KAT6B (MORF; MOZ2; MYST4) (KAT6B)
Mechanism
Inhibitor of KAT6 (MYST histone acetyltransferase) (KAT6A) and KAT6B (MORF; MOZ2; MYST4) (KAT6B)
Pathways
histone acetylation, gene expression regulation, cell cycle regulation
Therapy area
Renal & urology
Developer
Pfizer (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
GN6DU4ZE30

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07933848 Phase 1 Renal Impairment Not yet recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy AdultsRenal Impairment

Other drugs acting on KAT6A / KAT6B

More from Pfizer

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Prifetrastat

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.